The estrogen metabolite 17β-dihydroequilenin counteracts interleukin-1α induced expression of inflammatory mediators in human endothelial cells in vitro via NF-κB pathway

Summary

In most studies showing cardio- and vasculoprotective effects of estrogens, 17β-estradiol was used and little information on possible effects of different estrogen metabolites is yet available. We investigated whether particular estrogen metabolites are effective in counteracting inflammatory activation of human endothelium. Human endothelial cells were incubated with 17α-dihydroequilenin, 17β-dihydroequilenin, δ-8,9-dehydroestrone, estrone and 17β-estradiol and stimulated with interleukin (IL)-1α.The expression of IL-6, IL-8 and monocyte chemoattractant protein-1 (MCP-1) was determined. 17β-dihydroequilenin and 17β-estradiol at a concentration of 1µM reduced IL-1α-induced up regulation of IL-6, IL-8 and MCP-1 close to control levels. When both compounds were used in combination an additive effect was observed. 17α-dihydroequilenin and δ-8,9-dehydroestrone showed a similar anti-inflammatory effect only when used at 10µM whereas estrone had no effect. The effect of 17β-dihydroequilenin on IL-1α-induced production of IL-6, IL-8 and MCP-1 was reversed by the estrogen receptor antagonist ICI 182,780. 17β-dihydroequilenin also inhibited IL-1α-induced translocation of p50 and p65 to the nucleus of the cells. We have identified the estrogen metabolite 17β-dihydroequilenin, as an inhibitor of inflammatory activation of human endothelial cells. Characterization of specific estrogens – as shown in our study – could provide the basis for tailored therapies, which might be able to achieve vasoprotection without adverse side effects.

Keywords

Estrogens - endothelial cells - cardiovascular effects - inflammation - cytokines

^* Both authors contributed equally to this study.

• References

• 1 Braunwald E. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-9.
• 2 Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997; 95: 252-64.
• 3 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. Jama 1995; 273: 199-208.
• 4 Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11.
• 5 Pervin S, Singh R, Rosenfeld ME. et al. Estradiol suppresses MCP-1 expression In vivo : implications for atherosclerosis. Arterioscler Thromb Vasc Biol 1998; 18: 1575-82.
• 6 Sukovich DA, Kauser K, Shirley FD. et al. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol. Arterioscler Thromb Vasc Biol 1998; 18: 1498-505.
• 7 Miller AP, Feng W, Xing D. et al. Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 2004; 110: 1664-9.
• 8 Keck C, Herchenbach D, Pfisterer J. et al. Effects of 17beta-estradiol and progesterone on interleukin-6 production and proliferation of human umbilical vein endothelial cells. Exp Clin Endocrinol Diabetes 1998; 106: 334-9.
• 9 Seli E, Pehlivan T, Selam B. et al. Estradiol downregulates MCP-1 expression in human coronary artery endothelial cells. Fertil Steril 2002; 77: 542-7.
• 10 Caulin-Glaser T, Watson CA, Pardi R. et al. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996; 98: 36-42.
• 11 Rodriguez E, Lopez R, Paez A. et al. 17Beta-estradiol inhibits the adhesion of leukocytes in TNF-alpha stimulated human endothelial cells by blocking IL-8 and MCP-1 secretion, but not its transcription. Life Sci 2002; 71: 2181-93.
• 12 Simoncini T, Maffei S, Basta G. et al. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res 2000; 87: 19-25.
• 13 Caulin-Glaser T, Garcia-Cardena G, Sarrel P. et al. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 1997; 81: 885-92.
• 14 Hamilton KL, Mbai FN, Gupta S. et al. Estrogen, heat shock proteins, and NFkappaB in human vascular endothelium. Arterioscler Thromb Vasc Biol 2004; 24: 1628-33.
• 15 Strehlow K, Werner N, Berweiler J. et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003; 107: 3059-65.
• 16 Hulley S, Grady D, Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama 1998; 280: 605-13.
• 17 Rossouw JE, Anderson GL, Prentice RL. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama 2002; 288: 321-33.
• 18 Dubey RK, Jackson EK. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol 2001; 280: F365-88.
• 19 Dubey RK, Gillespie DG, Grogli M. et al. Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors. J Clin Endocrinol Metab 2004; 89: 852-9.
• 20 Mukherjee TK, Nathan L, Dinh H. et al. 17-epiestriol, an estrogen metabolite, is more potent than estradiol in inhibiting vascular cell adhesion molecule 1 (VCAM-1) mRNA expression. J Biol Chem 2003; 278: 11746-52.
• 21 Waters DD, Alderman EL, Hsia J. et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. Jama 2002; 288: 2432-40.
• 22 Wojta J, Zoellner H, Gallicchio M. et al. Gammainterferon counteracts interleukin-1 alpha stimulated expression of urokinase-type plasminogen activator in human endothelial cells in vitro . Biochem Biophys Res Commun 1992; 188: 463-9.
• 23 Tschugguel W, Dietrich W, Zhegu Z. et al. Differential regulation of proteasome-dependent estrogen receptor alpha and beta turnover in cultured human uterine artery endothelial cells. J Clin Endocrinol Metab 2003; 88: 2281-7.
• 24 Bochkov VN, Mechtcheriakova D, Lucerna M. et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood 2002; 99: 199-206.
• 25 Marin V, Montero-Julian FA, Gres S. et al. The IL6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol 2001; 167: 3435-42.
• 26 Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. Faseb J 1992; 06: 2591-9.
• 27 Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002; 55: 714-26.
• 28 Turgeon JL, McDonnell DP, Martin KA. et al. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2004; 304: 1269-73.
• 29 Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996; 94: 727-33.
• 30 Zhang X, Wang LY, Jiang TY. et al. Effects of testosterone and 17-beta-estradiol on TNF-alpha-induced E-selectin and VCAM-1 expression in endothelial cells. Analysis of the underlying receptor pathways. Life Sci 2002; 71: 15-29.
• 31 Mukherjee TK, Dinh H, Chaudhuri G. et al. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 2002; 99: 4055-60.
• 32 Bhavnani BR. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer’s. J Steroid Biochem Mol Biol 2003; 85: 473-82.
• 33 Dey M, Lyttle CR, Pickar JH. Recent insights into the varying activity of estrogens. Maturitas 2000; (34) (Suppl. 02) S25-33.
• 34 McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999; 20: 435-59.
• 35 Ghosh S, Gifford AM, Riviere LR. et al. Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell 1990; 62: 1019-29.
• 36 De Martin R, Hoeth M, Hofer-Warbinek R. et al. The transcription factor NF-kappaB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000; 20: E83-8.
• 37 Galea E, Santizo R, Feinstein DL. et al. Estrogen inhibits NF kappa B-dependent inflammation in brain endothelium without interfering with I kappa B degradation. Neuroreport 2002; 13: 1469-72.
• 38 Ho KJ, Liao JK. Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol 2002; 22: 1952-61.
• 39 Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53: 605-19.